Silo Pharma's stock experienced fluctuations on Tuesday, initially rising before declining into negative territory.
The company announced its participation in a program aimed at enhancing the development and optimization of QwikAgents, an artificial intelligence platform. This initiative is set to expand the platform's capabilities for both consumers and enterprises, targeting a range of users from individuals to developers and businesses. QwikAgents will allow users to deploy customizable AI agents for various applications, including research, content generation, and workflow automation, with starter plans anticipated to start at $14 per month.
Additionally, Silo Pharma is collaborating with AMD to leverage its developer resources, which is expected to enhance platform performance and reliability. This partnership aims to facilitate the scalable deployment of autonomous AI agents that can perform tasks with minimal human input.
Beyond its AI endeavors, Silo Pharma continues to focus on developing biopharmaceutical therapies for conditions such as stress-induced psychiatric disorders and chronic pain. Their product pipeline includes treatments for post-traumatic stress disorder and fibromyalgia, as well as a preclinical program for Alzheimer's disease. As of Tuesday, Silo Pharma's stock was down 4.36%, trading at $5.05.